Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Mar 17

PMID 35296099

Authors

Angela Ceribelli

Natasa Isailovic

Carolina Gorlino

Roberto Assandri

Matteo Vecellio

Maria De Santis

Minoru Satoh

Carlo Selmi

Affiliations

Soon will be listed here.

Abstract

Introduction: Antimitochondrial antibodies (AMAs) are the hallmark of primary biliary cholangitis (PBC) but can be identified also in patients with connective tissue disease, namely, systemic sclerosis (SSc). Protein immunoprecipitation (IP) and IP-Western blot (WB) can be used to confirm AMA positivity directed at the pyruvate dehydrogenase complex (PDC) subunits E1α, E1β, E2/E3, and E3BP in patients showing a cytoplasmic reticular pattern at indirect immunofluorescence when performed in a screening setting before the onset of overt cholestasis in rheumatic patients.

Patients And Methods: We studied sera from 285 patients affected by connective tissue disease [SSc, n = 144; dermato/polymyositis (DM/PM), n = 56; and undifferentiated connective tissue disease (UCTD), n = 85] by indirect immunofluorescence (IIF), protein-IP, and IP-WB to identify specific PDC subunits recognized by AMA.

Results: Twenty percent (57/285) of sera from patients with connective tissue disease had a cytoplasmic reticular pattern at IIF, and in 77% (44/57, including 20 SSc, 12 PM/DM, and 12 UCTD) of these, we detected different titers of autoantibodies against the PDC subunits, specifically against PDC-E2. Among these sera, 4 (9%) tested positive for anti-E1α, 15 (34%) for anti-E1β, and 16 (36%) for anti-E3BP. Four of the 20 AMA-positive SSc cases (20%) had been already diagnosed with PBC, and all were positive for autoantibodies against the subunits PDC-E2, E3, and E3BP.

Conclusions: Using IIF and IP, we confirm that autoantibodies against the PDC components are detected in rheumatic patients with PBC or without liver dysfunction. In view of the strong predictive value of AMA for PBC, a strict follow-up of these latter patients is warranted for an early diagnosis of the disease.

Citing Articles

Clinical relevance and frequency of cytoplasmic patterns observed in ANA-Hep-2: experience of Cairo University Hospitals.

Abdelraouf F, Soliman O, Khateeb E, Mostafa A Immunol Res. 2024; 72(6):1515-1527.

PMID: 39432152 DOI: 10.1007/s12026-024-09551-z.

Evaluation strategy of anti-mitochondrial antibodies M2-negative: the role of multiplex rodent tissues and related clinical implications.

Tolassi C, Assandri R Gastroenterol Hepatol Bed Bench. 2024; 17(1):1-7.

PMID: 38737930 PMC: 11080696. DOI: 10.22037/ghfbb.v17i1.2879.

Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity.

Favoino E, Grapsi E, Barbuti G, Liakouli V, Ruscitti P, Foti C Clin Exp Immunol. 2023; 212(1):32-38.

PMID: 36715304 PMC: 10081109. DOI: 10.1093/cei/uxad012.

References

Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S . The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014; 48-49:50-2. DOI: 10.1016/j.jaut.2014.01.019. View

Jiang J, Baiesc F, Hiromasa Y, Yu X, Hui W, Dai X . Atomic Structure of the E2 Inner Core of Human Pyruvate Dehydrogenase Complex. Biochemistry. 2018; 57(16):2325-2334. PMC: 6033517. DOI: 10.1021/acs.biochem.8b00357. View

Calise S, Zheng B, Hasegawa T, Satoh M, Isailovic N, Ceribelli A . Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clin Chem Lab Med. 2018; 56(10):1789-1798. PMC: 8128709. DOI: 10.1515/cclm-2017-1152. View

Ceribelli A, Isailovic N, De Santis M, Selmi C . Comment on: Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Semin Arthritis Rheum. 2018; 48(4):e23-e24. DOI: 10.1016/j.semarthrit.2018.03.014. View

Albayda J, Khan A, Casciola-Rosen L, Corse A, Paik J, Christopher-Stine L . Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Semin Arthritis Rheum. 2017; 47(4):552-556. PMC: 6581062. DOI: 10.1016/j.semarthrit.2017.06.004. View

Leung P, Coppel R, Ansari A, Munoz S, Gershwin M . Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis. 1997; 17(1):61-9. DOI: 10.1055/s-2007-1007183. View

Targoff I, Miller F, Medsger Jr T, Oddis C . Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1998; 9(6):527-35. DOI: 10.1097/00002281-199711000-00008. View

Cancado E, Harriz M . The Importance of Autoantibody Detection in Primary Biliary Cirrhosis. Front Immunol. 2015; 6:309. PMC: 4477174. DOI: 10.3389/fimmu.2015.00309. View

De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G . Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005; 6:96. PMC: 1208954. DOI: 10.1186/1465-9921-6-96. View

10.

Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L . Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2013; 73(12):2087-93. DOI: 10.1136/annrheumdis-2013-203716. View

11.

Bowlus C, Gershwin M . The diagnosis of primary biliary cirrhosis. Autoimmun Rev. 2014; 13(4-5):441-4. PMC: 3987745. DOI: 10.1016/j.autrev.2014.01.041. View

12.

Poormoghim H, Lucas M, Fertig N, Medsger Jr T . Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000; 43(2):444-51. DOI: 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G. View

13.

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

14.

Muratori L, Granito A, Muratori P, Pappas G, Bianchi F . Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis. 2008; 12(2):261-76. DOI: 10.1016/j.cld.2008.02.009. View

15.

Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W . The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology. 2017; 65(5):1670-1682. PMC: 5397331. DOI: 10.1002/hep.29059. View

16.

Palmer J, Jones D, Quinn J, McHugh A, Yeaman S . Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology. 1999; 30(1):21-6. DOI: 10.1002/hep.510300106. View

17.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M . Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012; 14(2):R97. PMC: 3446471. DOI: 10.1186/ar3822. View

18.

Tanaka A, Miyakawa H, Luketic V, Kaplan M, Storch W, Gershwin M . The diagnostic value of anti-mitochondrial antibodies, especially in primary biliary cirrhosis. Cell Mol Biol (Noisy-le-grand). 2002; 48(3):295-9. View

19.

Villalta D, Sorrentino M, Girolami E, Tampoia M, Alessio M, Brusca I . Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clin Chim Acta. 2014; 438:135-8. DOI: 10.1016/j.cca.2014.08.024. View

20.

Vierling J . Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis. 2004; 8(1):177-94. DOI: 10.1016/S1089-3261(03)00132-6. View